Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition

IntroductionApproximately 50% of melanomas harbor an activating BRAFV600E mutation. Standard of care involves a combination of inhibitors targeting mutant BRAF and MEK1/2, the substrate for BRAF in the MAPK pathway. PTEN loss-of-function mutations occur in ~40% of BRAFV600E melanomas, resulting in i...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Evan DuBose, Samantha M. Bevill, Dana K. Mitchell, Noah Sciaky, Brian T. Golitz, Shelley A. H. Dixon, Steven D. Rhodes, James E. Bear, Gary L. Johnson, Steven P. Angus
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-05-01
coleção:	Frontiers in Oncology
Assuntos:	melanoma kinase inhibitor drug synergy ERBB3 resistance
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1191217/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!